Akebia Therapeutics Inc.
AKBA | NASDAQ
$0.94
+$0.02 (+2.65%)
At close: Sep 21, 2026, 4:00 PM ET
$0.95
+$0.01 (+0.74%)
Pre-market:
Sep 22, 2026, 8:44 AM ET
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | 236.2M | 160.18M | 194.62M | 292.48M | 211.65M | 294.64M |
Cost of Revenue | 39.46M | 63.18M | 74.15M | 22.5M | 81.49M | 63.96M |
Gross Profit | 196.73M | 97M | 120.47M | 269.99M | 130.16M | 230.68M |
Operating Income | 23.5M | -50.47M | -46.26M | -80.78M | -264.5M | -377.83M |
Interest Income | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Income | -3.72M | -69.41M | -51.93M | -94.23M | -282.02M | -384.84M |
Net Income | -5.35M | -69.41M | -51.93M | -94.23M | -282.02M | -384.84M |
Selling & General & Admin | 107.48M | 106.55M | 100.23M | 138.6M | 174.14M | 154.1M |
Research & Development | 62.36M | 37.65M | 63.08M | 165.99M | 147.85M | 218.49M |
Other Expenses | 3.4M | 3.28M | 3.42M | 46.18M | 72.67M | 235.92M |
Operating Expenses | 173.24M | 147.48M | 166.73M | 350.77M | 394.66M | 608.51M |
Interest Expense | 24.18M | 18.19M | 6.03M | 15.69M | 19.94M | 8.87M |
Selling & Marketing Expenses | n/a | n/a | 100.23M | 6.7M | 8.2M | 5M |
Cost & Expenses | 212.7M | 210.65M | 240.88M | 373.26M | 476.15M | 672.47M |
Income Tax Expense | 1.62M | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 257.16M | 210.95M | 187.47M | 182.78M | 165.95M | 138.46M |
Shares Outstanding (Diluted) | 257.16M | 210.95M | 187.47M | 182.78M | 165.95M | 138.46M |
EPS (Basic) | -0.02 | -0.33 | -0.28 | -0.58 | -1.48 | -2.53 |
EPS (Diluted) | -0.02 | -0.33 | -0.28 | -0.58 | -1.48 | -2.53 |
EBITDA | 21.73M | -13.72M | -8.27M | 3.06M | -189.91M | -139.83M |
EBIT | 20.46M | -51.23M | -45.89M | -34.64M | -227.88M | -174.52M |
Depreciation & Amortization | 1.27M | 37.5M | 37.63M | 37.7M | 37.97M | 34.69M |
Add to Watchlist
Select watchlists to add or remove AKBA